Groves Morris D
UT MD Anderson Cancer Center, Department of Neuro-Oncology, 1400 Holcombe Blvd, Unit 431, Houston, TX 77030, USA.
Arch Neurol. 2010 Mar;67(3):305-12. doi: 10.1001/archneurol.2010.18.
The management of patients with leptomeningeal metastases (LM) is multifaceted and complex. Even with an aggressive approach, therapeutic outcomes are uniformly disappointing. This is because of the relentless growth of the central nervous system (CNS) and/or the systemic cancers, or their lethal complications. Advances in the understanding of the homing of cancer cells to the CNS, and of cancer metastasis in general, and more effective anticancer drugs that are adequately delivered to the CNS and cerebrospinal fluid (CSF) are needed to improve outcomes for patients with LM. These advances may lead to better treatments for this disease and, ultimately, its prevention.
柔脑膜转移(LM)患者的管理是多方面且复杂的。即便采取积极的治疗方法,治疗结果总体上仍令人失望。这是由于中枢神经系统(CNS)和/或全身性癌症的持续生长,或其致命并发症所致。需要在理解癌细胞归巢至CNS以及一般癌症转移方面取得进展,并且需要有能充分递送至CNS和脑脊液(CSF)的更有效的抗癌药物,以改善LM患者的治疗结果。这些进展可能会带来针对这种疾病的更好治疗方法,并最终实现对其预防。